medigraphic.com
ISSN 1405-1710 (Print)

2003, Number 1

<< Back Next >>

Rev Cent Dermatol Pascua 2003; 12 (1)

Tacrolimus for the treatment of inflammatory skin disease

Jiménez HF, Vidal FA

Language: Spanish
References: 32
Page: 42-48
PDF size: 81.44 Kb.


ABSTRACT

Tacrolimus has been show to be a powerful suppressor of the immune system. It was first introduce to prevent allograft rejection and is now routinely used in kidney, liver and heart transplantation. Is the prototype of a new class of topical immunomodulators (TIM) for the treatment of inflammatory skin disease, above all atopic dermatitis, but is not the only disease that’s been tested and the indications are likely to grow. The objective of this review is to express the knowledge of the mechanism, possible indications in dermatology, dosage and adverse reactions of tacrolimus.


REFERENCES

  1. Ruzicka, Assmann. Tacrolimus, the drug for the turn of the millennium? Arch Dermatol 1999; 135: 574-580.

  2. Nasr. Topical tacrolimus in dermatology. Clin Exp Dermatol 2000; 25: 250-254.

  3. Nhgiem. Topical immunomodulators?, introducing old friends and a new ally, tacrolimus. J Am Acad Dermatol 2001; 44: 111-113.

  4. Bekersky, Fitzsimmons. Non clinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001; 44: s17-s27.

  5. Reitamo. Tacrolimus: A new topical immunomodulatory therapy for atopic dermatitis. J Allergy Clin Immunol 2001; 107: 445-448.

  6. Soter, Fleischer. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, Safty. J Am Acad Dermatol 2001; 44: s39-s46.

  7. Allen, Stegfried. Significant absorption of topical tacrolimus in 3 patiens with Netherton Syndrome. Arch Dermatol 2001; 137: 747-750.

  8. Quelle-Roussel, correspondence. Topical tacrolimus and pimecrolimus are not associated with skin atrophy. Reply from author. British Journal of Dermatology 2002; 146: 343.

  9. Lebwohl, Suad. Treatment of psoriasis. Part 2 systemic therapies. J Am Acad Dermatol 2001; 45: 649-661.

  10. Lyon, Kirby. Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. British Journal of Dermatology 1999; 140: 562-564.

  11. Jolles, Niclasse. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. 1999; 140: 565.

  12. Zonneveld, Rubins. Topical tacrolimus is not effective in chronic plaque psoriasis. Arch Dermatol 1998; 134: 1101-1102.

  13. Bos. Topical tacrolimus and pimecrolimus are not associated with skin atrophy. British Journal of Dermatology 2002; 146: 342.

  14. Remitz, Reitamo. Tacrolimus ointment improves psoriasis in a microplaque assay. British Journal of Dermatology 1999; 141: 103-107.

  15. Fleisher. Treatment of atopic dermatitis: Role of tacrolimus ointment as a topical non corticosteroidal therapy. J Allergy Clin Immunol 1999; 104: s126-130.

  16. Hanifin, Ling. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients. Part I, efficacy. J Am Acad Dermatol 2001; 44: s29-s38.

  17. Reitamo, Wollenberg. Safety and efficacy of 1 year tacrolimus ointment monotheray in adults with atopic dermatitis. Arch Dermatol 2000; 136: 999-1006.

  18. Sugiura. Long term efficacy of tacrolimus ointment for recalcitrant facial erythema resistant to topical corticosteroids in adult patients with atopic dermatitis. Arch Dermatol 2000; 136: 1062-1063.

  19. Paller, Lawrence. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44: s47-s57.

  20. Boguniewicz, Fiedler. A randomized, vehicle controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children J Allergy Clin Immunol 1998; 102: 637-644.

  21. Kang, Lucky. Long term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44: s58-s64.

  22. Drake, Prendergast. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001; 44(Suppl): S65-72.

  23. Thiers. Topical tacrolimus: treatment failure in a patient with alopecia areata. Arch Dermatol 2000; 136: 124.

  24. Reich, Vente. Topical tacrolimus for Pyoderma gangrenosum. British Journal of Dermatology 1998; 139: 755-756.

  25. Vente, Reich. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. British Journal of Dermatology 1999; 140: 338-342.

  26. Goldman. Tacrolimus ointment for the treatment of steroid induced rosacea: A preliminary report. J Am Acad Dermatol 2001; 44: 995-998.

  27. Choi, Nghiem. Tacrolimus ointment in the treatment of chronic coetaneous graft vs host disease. Arch Dermatol 2001; 137: 1202-120.

  28. Kim, DiCarlo. Are keloids really “gli-loids”?: High level expression of Gli-1 oncogene in keloids. J Am Acad Dermatol 2001;45:707-711.

  29. Redondo-Bellon. Chromoblastomycosis produced by Aureobasidium pullulans in an immunosuppressed patient. 1997; 133: 663-664.

  30. Blackwell, Ahmed. Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus in a renal transplant patient. British Journal of Dermatology 2000; 143: 873-875.

  31. Assman, Homey. Applications of tacrolimus for the treatment of skin disorders. Immunopharmacology 2000; 47: 203-213.

  32. Sugiura, Uehara. An open study of lotion formulation to improve tolerance of tacrolimus in facial atopic dermatitis. 2001; 145: 795-798.




2020     |     www.medigraphic.com